Compare · CERS vs INFY
CERS vs INFY
Side-by-side comparison of Cerus Corporation (CERS) and Infosys Limited (INFY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CERS and INFY operate in EDP Services (Technology), so they compete in similar markets.
- INFY is the larger of the two at $45.07B, about 76.8x CERS ($587.1M).
- Over the past year, CERS is up 116.2% and INFY is down 35.3% - CERS leads by 151.4 points.
- INFY has been more active in the news (5 items in the past 4 weeks vs 3 for CERS).
- INFY has more recent analyst coverage (25 ratings vs 4 for CERS).
- Company
- Cerus Corporation
- Infosys Limited
- Price
- $2.94+2.08%
- $11.11+3.64%
- Market cap
- $587.1M
- $45.07B
- 1M return
- +11.57%
- +1.28%
- 1Y return
- +116.18%
- -35.26%
- Industry
- EDP Services
- EDP Services
- Exchange
- NASDAQ
- NYSE
- IPO
- 1997
- News (4w)
- 3
- 5
- Recent ratings
- 4
- 25
Cerus Corporation
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation has collaboration with LifeSouth Community Blood Centers to manufacture INTERCEPT Fibrinogen Complex. The company was incorporated in 1991 and is headquartered in Concord, California.
Infosys Limited
Infosys Limited, together with its subsidiaries, provides consulting, technology, outsourcing, and next-generation digital services in North America, Europe, India, and internationally. It provides application development and management, independent validation, product engineering and management, infrastructure management, enterprise application management, and support and integration services. The company's products and platforms include Finacle, a core banking solution; Edge suite of products; Infosys Nia, an artificial intelligence platform; Infosys McCamish - an insurance platform; Wingspan, a customizable learning platform; Stater mortgage servicing platform; Panaya automation suite; and Skava, an e-commerce suite. The company serves clients in the financial services and insurance, life sciences and healthcare, manufacturing, retail, consumer packaged goods and logistics, hi-tech, communications, telecom OEM, media, energy, utilities, resources, services, and other industries. It has collaboration agreements with Rolls-Royce, BP plc, Newmont Corporation, RXR Realty, Majesco Limited, and Centre for Accessibility Australia. The company was formerly known as Infosys Technologies Limited and changed its name to Infosys Limited in June 2011. Infosys Limited was incorporated in 1981 and is headquartered in Bengaluru, India.
Latest CERS
- Chief Executive Officer Jayaraman Vivek K sold $52,665 worth of shares (16,666 units at $3.16) as part of a pre-agreed trading plan, decreasing direct ownership by 0.74% to 2,232,211 units (SEC Form 4)
- Cerus Corporation to Release Second Quarter 2026 Financial Results on July 30, 2026
- Cerus Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Chief Financial Officer Green Kevin Dennis sold $99,105 worth of shares (33,676 units at $2.94) as part of a pre-agreed trading plan and gave a grant of 63,600 shares, decreasing direct ownership by 8% to 1,062,188 units (SEC Form 4) to cover withholding tax
- Chief Operating Officer Jayaraman Vivek K was granted 554,529 shares, gave a grant of 80,000 shares and sold $124,658 worth of shares (42,359 units at $2.94) as part of a pre-agreed trading plan, increasing direct ownership by 24% to 2,248,877 units (SEC Form 4) to satisfy withholding obligation
- Chief Legal Officer Jensen Chrystal gave a grant of 55,000 shares and sold $71,598 worth of shares (24,329 units at $2.94) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 966,657 units (SEC Form 4) (for withholding tax)
- President and CEO Greenman William Mariner gave a grant of 192,500 shares and sold $299,937 worth of shares (101,919 units at $2.94) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 5,053,036 units (SEC Form 4) to cover taxes
- Cerus to Showcase New Evidence, Innovation and Global Experience with the INTERCEPT Blood System at the 39th International ISBT Congress
- Director Bjerkholt Eric sold $53,180 worth of shares (20,454 units at $2.60), decreasing direct ownership by 7% to 261,679 units (SEC Form 4)
- Cerus Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation
Latest INFY
- Infosys downgraded by Analyst with a new price target
- Infosys downgraded by HSBC Securities
- SEC Form 6-K filed by Infosys Limited
- Infosys: AI Revenues at 8.2% in Q1; Resilient Operating Margin of 21.1%
- SEC Form 6-K filed by Infosys Limited
- Wells Fargo initiated coverage on Infosys with a new price target
- SEC Form 6-K filed by Infosys Limited
- SEC Form 6-K filed by Infosys Limited
- Infosys Collaborates with Sentara to Unlock AI Value and Scale Enterprise AI Adoption in Healthcare Services
- Infosys, ANA's Global CMO Growth Council, and LIONS Unveil the CMO AI Hub